Welcome to the MDS 2021 Interactive Programme
The congress will officially run on Eastern Daylight Time Zone EDT (Toronto time zone, UTC-4)
To convert the meeting times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A at the end
The viewing of sessions cannot be accessed from this congress calendar. All sessions are accessible via the Virtual Platform
Introduction (ID 240)
What we learn from real-world registries (ID 45)
Oral Presentation: Burden and Management of Acute Myocardial Infarction in Myelodysplastic Syndrome (MDS) (ID 176)
Abstract
Background And Aims
Majority of MDS patients suffer with coronary artery disease (CAD). Anaemia and thrombocytopaenia pose unique challenges for the management of CAD due to increased bleeding risk. We aim to assess burden and management of acute CAD in MDS.
Methods
Medical records of cardiac hospitalisations were analysed in 910 patients registered in the South Australian MDS registry.
Results
During median follow-up of 28.5 (95% CI 10.8-68.6) months, 274 (30%) patients required 336 hospitalisations for cardiac causes.
Complete data were available for 84 of the 91 hospitalisations for CAD, of which 51 (60.7%) were due to Type 1 myocardial infarction (MI), consisting of 38 cases of non-ST elevation MI (NSTEMI) and 7 of ST-elevation MI (STEMI). Overall, 43 out of the total 910 patients (5%) had an admission for Type 1 MI with 8 of these having more than one MI during study period.
Coronary angiography was performed in only 37% of cases of Type 1 MI and percutaneous coronary intervention in 20%. Meanwhile, all guideline-recommended pharmacotherapies were under-prescribed at discharge: 78% use of antiplatelets, 62% statins, 51% beta-blockers, 38% ACE inhibitors/angiotensin receptor blockers. 25% patients had bleeding during or within 6-months of index admission for Type I MI. Re-admission with CAD was 18% following type I MI.
Conclusions
Our data reveal an alarming tendency to manage patients with MI conservatively, with under-utilisation of all guideline-recommended therapies often in the absence of absolute contraindications. This highlights an unmet need for developing guidelines to manage cardiac co-morbidities in MDS.